Due to the known anti-tumor activities of VEGFR and EGFR inhibitors in advanced HCC, vandetanib was evaluated in a phase II study but did not show any statistically significant in PFS or OS as compared to placebo [125]. The gene discussed is KDR; the disease is hepatocellular carcinoma.